---

---

tags : Trial    symbols : Fnctf   

save search

---

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| 0.0% | O: -100.0% H: NaN% C: Infinity%
GILD | $67.07 0.06% 0.06% 8.3M |

Health Technology

| -1.53% | O: 0.5% H: 0.83% C: 0.28%
CTXR | $0.7199 -6.18% -6.58% 880K |

Health Technology

| -15.31% | O: 2.33% H: 2.28% C: -4.23%
hope treatment pharmaceuticals city for car-t trial

---

GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| -2.91% | O: 0.17% H: 0.0% C: -0.43%
gammatile tumors for trial

---

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published: 2024-03-21 (Crawled : 12:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M |

Health Technology

| 2.54% | O: -0.13% H: 0.4% C: -0.06%
ylynk-006 keytruda lung merck update cancer cell trial plus

---

City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
Published: 2024-03-07 (Crawled : 12:30) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| -1.93% | O: 0.79% H: 0.78% C: 0.78%
MBIO | $0.35 -2.7% -2.77% 120K |

Health Technology

| -73.48% | O: 8.33% H: 4.2% C: -2.8%
FBIO | $1.785 -1.38% -1.4% 120K |

Health Technology

| -19.19% | O: 2.93% H: 0.0% C: -9.21%
tumors cell city trial therapy

---

City of Hope presents pivotal clinical trial data at American Society of Hematology (ASH) conference on revumenib, a potential new targeted therapy for high-risk subtypes of acute leukemias
Published: 2023-12-12 (Crawled : 21:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| -6.45% | O: -0.07% H: 1.35% C: -0.1%
conference hope city trial potential therapy

---

Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
Published: 2023-12-07 (Crawled : 18:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M |

Health Technology

| 20.23% | O: -0.04% H: 0.01% C: -1.61%
ylynk-008 keytruda lung merck cancer cell trial plus

---

Nokia and Orange set record with 800Gbps transmission trial on 6,600km Dunant live network to prepare for soaring traffic on strategic trans-Atlantic route
Published: 2023-12-06 (Crawled : 08:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
set network trial

---

BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
BTAI | News | $2.7 -9.09% -10.0% 880K |

Health Technology

| -50.82% | O: -35.39% H: 19.38% C: 18.54%
fda update trial therapeutics financial results

---

Viking Therapeutics to Highlight Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023
Published: 2023-10-10 (Crawled : 20:00) - prnewswire.com
VKTX | $65.03 0.15% 0.15% 2.6M |

Health Technology

| 473.3% | O: 1.32% H: 1.48% C: -5.13%
LGND | $70.87 1.4% 1.38% 150K |

Health Technology

| 17.65% | O: -0.58% H: 0.0% C: -1.88%
vk2735 obesityweek agonist presentation trial therapeutics

---

Inland Empire Trial Lawyer William D. Shapiro Elected National Vice President of the American Board of Trial Advocates (ABOTA)
Published: 2023-10-06 (Crawled : 20:00) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
trial

---

City of Hope Opens First U.S. Multicenter Clinical Trial for Robotic Single-Port Mastectomies for Breast Cancer Patients
Published: 2023-10-03 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
breast hope cancer city trial

---

Calidi Biotherapeutics and City of Hope Announce First Patient Dosed in a Phase 1 Clinical Trial Evaluating Neural Stem Cells Engineered to Carry an Oncolytic Virus, CLD-101, in Recurrent High-grade Glioma Patients
Published: 2023-07-18 (Crawled : 14:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
cld-101 hope city trial

---

Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
Published: 2023-07-17 (Crawled : 13:20) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| -2.62% | O: 4.62% H: 0.0% C: -1.54%
GILD | $67.07 0.06% 0.06% 8.3M |

Health Technology

| -13.1% | O: -0.67% H: 1.42% C: 1.06%
update trial therapeutics

---

Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
Published: 2023-06-26 (Crawled : 21:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 61.72% | O: 2.15% H: 1.18% C: 0.43%
SRNE | $0.015 -8.85% 56K |

Health Technology

| -97.13% | O: -1.0% H: 4.2% C: 1.3%
SGEN | $228.74 0.1% 20M |

Health Technology

| 16.38% | O: 0.82% H: 0.02% C: -0.85%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -12.85% | O: 0.17% H: 0.0% C: 0.0%
OMER | $3.04 -1.62% -1.64% 250K |

Health Technology

| -43.7% | O: 0.19% H: 2.22% C: 1.76%
IMGN | News | $31.23 0.03% 49M |

Health Technology

| 65.12% | O: 0.58% H: 2.57% C: 0.26%
companies pipeline trial

---

Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
Published: 2023-05-09 (Crawled : 15:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| -14.15% | O: -0.66% H: 0.0% C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M |

Health Technology

| -14.65% | O: -0.36% H: 1.23% C: 0.63%
lyn-005 schizophrenia trial therapeutics study

---

The Simon Law Group and The Trial Lab Secure Historic Verdict of $161 Million in Soulliere v. Suzuki Motor of America, Inc. Motorcycle Accident Case
Published: 2023-05-05 (Crawled : 16:00) - prnewswire.com
SZKMY | $45.94 -0.52% 16K |

Manufacturing

| -66.6% | O: 0.98% H: 0.88% C: 0.63%
group trial simon

---

Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
Published: 2023-03-23 (Crawled : 11:00) - prnewswire.com
NUVL | $67.21 -0.58% -0.58% 500K |

| 141.12% | O: 1.54% H: 0.88% C: -1.52%
nvl-655 lung cancer trial

---

BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Published: 2023-03-07 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
BICX | $0.75 201.91% 4.2K |

Health Care and Social Assistan...

| Email alert Add to watchlist
meeting trial positive results phase 1

---

Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
Published: 2023-02-21 (Crawled : 22:00) - biospace.com/
MRK | $127.0 0.1% -1.21% 7.1M |

Health Technology

| 15.96% | O: -0.57% H: 0.9% C: 0.16%
covid-19 trial update

---

AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| 5.28% | O: 7.92% H: 0.0% C: 0.0%
propel symposium trial asco results

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---